Tafero - EM Tablet (Emtricitabine (200mg) and Tenofovir Alafenamide (25mg))

Tafero - EM Tablet is a combination of antiretroviral medications as active ingredients, such as emtricitabine and tenofovir alafenamide. Emtricitabine belongs to the class of medication known as nucleoside reverse transcriptase inhibitors, and tenofovir alafenamide belongs to the class called nucleotide reverse transcriptase inhibitors.

Tafero – EM (emtricitabine and tenofovir alafenamide) is used in combination with other medicines to treat HIV-1 (human immunodeficiency virus) infection in adults and adolescents 12 years of age. It works by preventing the multiplication of viruses in the body and controlling the infection.

HIV

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Tafero - EM Tablet(Emtricitabine and tenofovir alafenamide) also causes some adverse impact on the body, most of which resolves without any medical attention. However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately​

Some common side effects include:
● Headache
● Diarrhea
● Vomiting
● Nausea
● Dizziness
● Rash
● Fatigue
● Weakness
● Abdominal pain
● Itching
● Increased transaminase level in blood
● Cough
● Back pain
● Glycosuria
● Increased creatine phosphokinase (CPK) level in blood
● Increased LDL cholesterol level in blood.

The doctor will decide the dose and duration of Tafero EM tablet (Emtricitabine and tenofovir alafenamide) based on the disease condition and other factors such as body weight and age. Swallow the whole tablet with a glass of water, as it is an orally available drug.

This tablet can be taken with or without food but at a fixed time every day to get better results. Take it exactly as advised by the doctor; don't miss a dose or overdose the medicine.

● Orkin, C., DeJesus, E., Sax, P. E., Arribas, J. R., Gupta, S. K., Martorell, C., ... & Martin, H. (2020). Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. The Lancet HIV, 7(6), e389-e400.
● Gallant, J. E., Daar, E. S., Raffi, F., Brinson, C., Ruane, P., DeJesus, E., ... & Rhee, M. S. (2016). Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. The lancet HIV, 3(4), e158-e165.
● Avihingsanon, A., Lu, H., Leong, C. L., Hung, C. C., Koenig, E., Kiertiburanakul, S., ... & Li, T. (2023). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. The Lancet HIV, 10(10), e640-e652.
● Deeks, E. D. (2018). Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs, 78(17), 1817-1828.